Welcome to our dedicated page for NEWCELX SEC filings (Ticker: NLSPW), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NewcelX Ltd. filings associated with NLSPW document foreign-issuer current reports, registration-statement references, material-event disclosures, shareholder voting matters, capital-structure items, governance matters, and clinical or regulatory updates. The records reflect the company’s public reporting transition from NLS Pharmaceutics-related securities to NewcelX as a Swiss clinical-stage regenerative medicine issuer.
Recent Form 6-K reports furnish press releases and investor presentations covering stem-cell-derived therapies, the NCEL-101 Type 1 Diabetes program, a stem-cell-derived islet replacement platform, and a strategic collaboration involving targeted immune modulation. The filing record also includes security-structure and registration disclosures, including references to Form F-3 registration statements and Form 20-F foreign private issuer reporting status.
NLS Pharmaceutics Ltd. – Schedule 13D filing (NLSPW)
Chairman Ronald Hafner has filed a Schedule 13D disclosing beneficial ownership of 557,131 common shares, equal to 13.2 % of the company’s 4,097,641 outstanding shares. Mr. Hafner possesses sole voting and dispositive power over the entire position; no shares are held jointly.
Capital deployment was entirely from personal funds. The filing details multiple transactions that built the position:
- Equity Purchase Agreement (10-Oct-2024): acquired 100,807 common shares plus 100,807 five-year warrants (exercise $4.25) at a combined price of $3.97.
- Warrant Amendment (9-Oct-2024): received pre-funded warrants for 1,925 shares, exercisable at CHF 0.80.
- Debt Purchase Agreement (10-Oct-2024): obtained 173,173 convertible preferred shares (conversion price $4.96) as part of a $4 m debt restructuring.
- Put-Call Agreement (Feb-2025): option exercised leading to purchase of 37,783 preferred shares for $150,000.
- Debt settlements: 111,637 common shares transferred from CEO Alexander Zwyer (7-Feb-2025) and 17,782 shares transferred from Magnetic Rock Investment AG (21-Feb-2025).
Intent: The shares are held for investment; no activist agenda is disclosed. The agreements grant limited participation rights (up to 50 % of future offerings for one year) but do not impose voting covenants. No criminal or civil proceedings are reported against the filer.
For investors, the filing signals material insider confidence and establishes Mr. Hafner as the company’s largest known shareholder, potentially aligning board decisions with shareholder value creation. No immediate dilution or earnings impact is indicated, but future conversions of preferred shares and warrant exercises could expand the float.